A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension